Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 20, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused...
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
March 08, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – ...
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
March 04, 2023 10:30 ET
|
Esperion Therapeutics, Inc.
– NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial...
Esperion Launches New Scientific Website
February 24, 2023 13:40 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared...
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
February 23, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Sheldon Koenig, president and chief executive officer, will present at Cowen’s 43rd annual Health...
CLEAR Outcomes Company Update Call: Detailed Results Discussion
February 22, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6th, 2023 where Esperion Chief Medical Officer...
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
February 21, 2023 07:00 ET
|
Esperion Therapeutics, Inc.
– Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secondary Endpoints; Additional Details in 11 Days...
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
February 20, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2023 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2023, the Compensation Committee of Esperion’s Board of Directors granted six new...
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial...